Table 2. Comparison of CTC enumerations with EpCAM and CSV antibodies in the same patients.
| Patient No. | CTC Count | P Value | Patient No. | CTC Count | P Value | Patient No. | CTC Count | P Value | |||
|---|---|---|---|---|---|---|---|---|---|---|---|
| EpCAM | CSV | EpCAM | CSV | EpCAM | CSV | ||||||
| LC (n = 20) | PDAC (n = 20) | BCa (n = 10) | |||||||||
| 1 | 0 | 3 | 0.1283 | 29 | 0 | 2 | 0.0011 | 59 | 6 | 10 | 0.9051 |
| 2 | 0 | 0 | 30 | 1 | 4 | 60 | 5 | 6 | |||
| 3 | 0 | 5 | 31 | 0 | 3 | 61 | 0 | 1 | |||
| 4 | 0 | 4 | 32 | 0 | 3 | 62 | 9 | 6 | |||
| 5 | 0 | 3 | 33 | 1 | 0 | 63 | 0 | 3 | |||
| 6 | 5 | 5 | 34 | 0 | 7 | 64 | 4 | 0 | |||
| 7 | 1 | 2 | 35 | 3 | 11 | 65 | 3 | 1 | |||
| 8 | 4 | 2 | 36 | 1 | 0 | 66 | 0 | 1 | |||
| 9 | 5 | 3 | 37 | 3 | 11 | 67 | 3 | 1 | |||
| 10 | 7 | 11 | 38 | 0 | 4 | 68 | 0 | 0 | |||
| 11 | 24 | 16 | 39 | 0 | 7 | HCC (n = 4) | |||||
| 12 | 12 | 13 | 40 | 0 | 1 | 69 | 0 | 0 | 0.5862 | ||
| 13 | 8 | 9 | 41 | 0 | 8 | 70 | 0 | 2 | |||
| 14 | 18 | 3 | 42 | 0 | 2 | 71 | 0 | 1 | |||
| 15 | 2 | 4 | 43 | 2 | 1 | 72 | 5 | 4 | |||
| 16 | 18 | 22 | 44 | 0 | 17 | CC (n = 8) | |||||
| 17 | 20 | 22 | 45 | 0 | 7 | 73 | 0 | 1 | 0.7995 | ||
| 18 | 11 | 14 | 46 | 1 | 4 | 74 | 9 | 2 | |||
| 19 | 5 | 5 | 47 | 3 | 2 | 75 | 1 | 2 | |||
| 20 | 0 | 4 | 48 | 2 | 1 | 76 | 0 | 2 | |||
| CRC (n = 8) | GC (n = 10) | 77 | 1 | 4 | |||||||
| 21 | 0 | 3 | 0.2065 | 49 | 0 | 4 | 0.2312 | 78 | 5 | 1 | |
| 22 | 2 | 0 | 50 | 0 | 4 | 79 | 2 | 2 | |||
| 23 | 4 | 0 | 51 | 0 | 2 | 80 | 0 | 6 | |||
| 24 | 0 | 2 | 52 | 0 | 1 | EC (n = 4) | |||||
| 25 | 20 | 9 | 53 | 0 | 1 | 81 | 1 | 2 | 0.1489 | ||
| 26 | 11 | 5 | 54 | 0 | 0 | 82 | 0 | 1 | |||
| 27 | 12 | 2 | 55 | 5 | 4 | 83 | 0 | 1 | |||
| 28 | 0 | 3 | 56 | 3 | 1 | 84 | 3 | 3 | |||
| 57 | 4 | 2 | OC (n = 4) | ||||||||
| Sarcoma (n = 3) | 58 | 1 | 5 | 85 | 3 | 3 | 0.5 | ||||
| 89 | 0 | 3 | 0.25 | 86 | 0 | 2 | |||||
| 90 | 0 | 5 | 87 | 0 | 1 | ||||||
| 91 | 0 | 9 | 88 | 1 | 1 | ||||||
Note:
CTC, circulating tumor cell; EpCAM, epithelial cell adhesion molecule; CSV, cell surface vimentin; No, number; n, sample number; LC, lung cancer; CRC, colorectal cancer; BCa, breast cancer; GC, gastric cancer; PDAC, pancreatic ductal adenocarcinoma; CC, cervical cancer; HNSCC, head and neck squamous cell carcinoma; EC, esophageal cancer; BC, brain cancer; N/A, not available; HCC, hepatocellular carcinoma; PCa, prostate cancer; OC, ovarian cancer; UC, bladder cancer.